Astellas Pharma Support Solutions
Astellas Pharma’s Support Solutions offers access and reimbursement support to help eligible patients overcome challenges to accessing Astellas products Table.
Astellas Support Solutions
Astellas Patient Assistance Program
The Astellas Patient Assistance Program provides Astellas oncology medicines at no cost to uninsured patients.
To enroll your patient in the Padcev Patient Assistance Program, call 888-402-0627 to obtain the application. The completed application can either be uploaded through the prescriber portal or faxed to 877-747-6843.
To enroll your patient in the Xospata Patient Assistance Program, call 844-632-9272 or upload completed application to the prescriber portal.
To enroll your patient in the Xtandi Patient Assistance Program, visit www.XTANDIaccess.com or call 855-898-2634.
Padcev Copay Assistance Program
The Padcev Copay Assistance Program helps commercially insured patients cover their out-of-pocket prescription costs for Padcev.
To enroll your patient in the Padcev Copay Assistance Program, contact Padcev Support Solutions at 888-402-0627.
Xospata Patient Savings Program
The Xospata Patient Savings Program helps commercially insured patients cover their out-of-pocket prescription costs for Xospata. To enroll your patient, visit XOSPATA Patient Savings Program. For more information, call 855-221-3493.
Xtandi Patient Savings Program
The Xtandi Patient Savings Program helps commercially insured patients cover their out-of-pocket prescription costs for Xtandi. To enroll your patient, visit Xtandi Patient Savings Program. For more information, call 855-217-8311.
Xospata/Xtandi Quick Start+ Program
The Quick Start+ Program provides a one-time, 7-day supply of Xospata or a 14-day supply of Xtandi at no cost to new eligible patients who experience a delay in insurance coverage.
Enrollment in the Quick Start+ Program is an option on the Xospata or Xtandi Patient Assistance Program Form.
TABLE Astellas Oncology Drugs
Padcev (romiplostim) Indications
In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy